Cethromycin is a ketolide antibiotic derived from erythromycin A being investigated for use in community-acquired pneumonia and other respiratory tract infections. Cethromycin possesses reliable activity against the bacteria most commonly associated with community-acquired pneumonia including S. pneumoniae, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, and L. pneumophila. Unlike fluoroquinolones, cethromycin has a narrower spectrum of activity against gram-negative bacteria, which may reduce the risk of collateral damage and the incidence of Clostridium difficile infection. It offers an advantage over telithromycin in that hepatotoxicity does not seem to be a concern. The FDA denied approval of cethromycin for the treatment of CAP in 2009, requesting more efficacy data.

Lobendazole is a metabolite of veterinary drug thiophanate. Lobendazole possesses teratogenic effect.

Stirimazole is an imidazole derivative patented by Lilly Industries Ltd. as an antiparasitic agent effective against Trypanosoma congolense, T. gambiense, T. rhodesiense, and T. cruzi. Stirimazole inhibited Trichomonas vaginalis in vitro at 0.225 μg/ml and eliminated infected lesions in mice at 20 mg/kg orally. Stirimazole eliminated intestinal amebiasis in rats at 50 mg/kg orally and hepatic amebiasis in hamsters at 100 mg/kg i.p. Stirimazole was curative against Trypanosoma rhodesiense, Trypanosoma cruzi, Trypanosoma gambiense, and Trypanosoma congolense in mice at 25, 100, 12.5, and 25 mg/kg (4 times, i.p.), respectively, and against Trypanosoma vivax in calves at 25 mg/kg i.v.

Sulfaproxyline is a sulfonamide derivative patented by J. R. Geigy A.-G. as an antibiotic, useful in the treatment of urinary tract infections. In preclinical models, sulfaproxyline is effective against staphylococci infection in guinea pigs. Bisulfon D, a drug product comprising the combination of sulfaproxyline and sulfamerazine has been used for the treatment of urinary tract infections in the puerperium.

Succisulfone is a sulfonamide derivative patented by Antoine Mouneyrat as antibiotic useful in the treatment of leprosy

Phthalylsulfamethizole is the sulfonamide. It was used as an antibacterial agent.

Stearylsulfamide is a sulfanilamide derivative patented by American Cyanamid Co. for the treatment of bacterial infections. Stearylsulfamide was never marketed.

Sulfasuccinamide is a sulfonamide antibacterial with properties similar to those of sulfamethoxazole. It has been applied topically in the treatment of local infections of the ear, nose, and throat. It has also been given as the sodium salt. Sulfasuccinamide is a carbonic anhydrase inhibitor.

Zoficonazole was developed as an antibacterial and an antifungal agent. Information about the current use of this compound is not available.

Torcitabine is the beta-L-enantiomer of the natural nucleoside D-cytidine. The drug was under development as an antiviral agent for the treatment of chronic hepatitis B virus infection. Torcitabine has poor oral bioavailability, but its 3’,5’-derivative ester (val-L-dC) and the 3’-monovaline ester, valtorcitabine dihydrochloride, have excellent oral bioavailability and consequently the torcitabine prodrug, valtorcitabine, has replaced torcitabine in clinical development. Torcitabine is active against hepadnaviruses, specifically human hepatitis B virus (HBV), duck hepatitis virus (DHBV) and woodchuck hepatitis virus (WHV). Torcitabine triphosphate is a selective inhibitor of the polymerase enzyme of HBV.